Keystonemab
Roland Meisel, Ph.D., is the Chief Commercial Officer at Keystonemab and has served as CEO and Founder of BLAC-BioPharma GmbH since March 2016, a consultancy specializing in the licensing of Biologics with a focus on Biosimilars. Additionally, Meisel is a Partner at Weissknight Corporate Finance, which aids business owners in enhancing company value through international M&A transactions and business optimization strategies. From August 2019 to July 2024, Meisel held the position of Vice President of Business Development & Licensing ex-China at Biotheus, overseeing licensing and co-development agreements. Other significant roles include Managing Director of Technical Operations at Saudi Biotechnology Manufacturing Co. and global Business Development responsibilities at The Biosimilars Group. Meisel's educational background includes a Ph.D. in Chemistry from Universität Rostock and graduate studies in carbohydrate chemistry at Purdue University.
This person is not in any teams
This person is not in any offices
Keystonemab
Keystonemab BV is an AI driven, big-data analytics platform leveraging real-time scientific information from millions of scientific, clinical & patent documents using AI to accelerate translation of knowledge from actionable insights of publications which supports in an unprecedented way. Our unique fish-net effect enables the identification of other active-ingredients influencing disease related signaling pathways, gene expressions, drug-targets and biomarkers for multi-drug, synergistic approach. We are specialized in: Identification of synergistic combinations of drugs and APIs Design of multi API new drug formulations for superior efficacy Clinical project rescue (e.g. lack of efficacy) with synergistic combinations Indication expansion of existing and newly developed drug (Drug repositioning) Differential biomarker analysis for identification of new druggable targets Commercial product portfolio analysis for development of market differentiating products Due diligence for in-licensing novel drugs